BCL2L1 and colorectal carcinoma: Overall, this study provided a new underlying mechanism for TRAF4-mediated radioresistance, suggesting that the TRAF4/JNK/Bcl-xL axis is a promising target for overcoming radioresistance during CRC treatment.